Delayed
Sapporo S.E.
07:06:56 14/05/2024 am IST
|
5-day change
|
1st Jan Change
|
831
JPY
|
-2.00%
|
|
-1.77%
|
+5.46%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
19,978
|
18,031
|
16,736
|
17,492
|
14,895
|
13,906
|
Enterprise Value (EV)
1 |
-689
|
-2,858
|
-4,796
|
-2,923
|
-6,179
|
-4,101
|
P/E ratio
|
9.48
x
|
8.61
x
|
8.19
x
|
11.8
x
|
5.35
x
|
5.13
x
|
Yield
|
2.01%
|
2.22%
|
2.39%
|
1.99%
|
2.58%
|
3.16%
|
Capitalization / Revenue
|
0.09
x
|
0.08
x
|
0.07
x
|
0.07
x
|
0.06
x
|
0.05
x
|
EV / Revenue
|
-0
x
|
-0.01
x
|
-0.02
x
|
-0.01
x
|
-0.02
x
|
-0.02
x
|
EV / EBITDA
|
-0.18
x
|
-0.79
x
|
-1.13
x
|
-1.06
x
|
-1.86
x
|
-1.07
x
|
EV / FCF
|
-0.15
x
|
-2.66
x
|
-7.54
x
|
2
x
|
-23.8
x
|
1.13
x
|
FCF Yield
|
-667%
|
-37.5%
|
-13.3%
|
50%
|
-4.2%
|
88.1%
|
Price to Book
|
0.41
x
|
0.35
x
|
0.32
x
|
0.32
x
|
0.27
x
|
0.24
x
|
Nbr of stocks (in thousands)
|
23,643
|
23,539
|
23,539
|
23,168
|
22,568
|
21,968
|
Reference price
2 |
845.0
|
766.0
|
711.0
|
755.0
|
660.0
|
633.0
|
Announcement Date
|
28/06/18
|
28/06/19
|
26/06/20
|
30/06/21
|
30/06/22
|
29/06/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
2,27,788
|
2,35,153
|
2,43,102
|
2,39,494
|
2,48,369
|
2,61,979
|
EBITDA
1 |
3,754
|
3,608
|
4,256
|
2,751
|
3,327
|
3,842
|
EBIT
1 |
2,542
|
2,488
|
3,027
|
1,483
|
2,132
|
2,647
|
Operating Margin
|
1.12%
|
1.06%
|
1.25%
|
0.62%
|
0.86%
|
1.01%
|
Earnings before Tax (EBT)
1 |
3,466
|
3,364
|
3,390
|
2,547
|
3,758
|
4,228
|
Net income
1 |
2,159
|
2,099
|
2,043
|
1,492
|
2,804
|
2,729
|
Net margin
|
0.95%
|
0.89%
|
0.84%
|
0.62%
|
1.13%
|
1.04%
|
EPS
2 |
89.12
|
88.93
|
86.79
|
63.98
|
123.4
|
123.4
|
Free Cash Flow
1 |
4,598
|
1,073
|
635.9
|
-1,461
|
259.5
|
-3,614
|
FCF margin
|
2.02%
|
0.46%
|
0.26%
|
-0.61%
|
0.1%
|
-1.38%
|
FCF Conversion (EBITDA)
|
122.48%
|
29.73%
|
14.94%
|
-
|
7.8%
|
-
|
FCF Conversion (Net income)
|
212.96%
|
51.11%
|
31.12%
|
-
|
9.25%
|
-
|
Dividend per Share
2 |
17.00
|
17.00
|
17.00
|
15.00
|
17.00
|
20.00
|
Announcement Date
|
28/06/18
|
28/06/19
|
26/06/20
|
30/06/21
|
30/06/22
|
29/06/23
|
Fiscal Period: März |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
20,667
|
20,889
|
21,532
|
20,415
|
21,074
|
18,007
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
4,598
|
1,073
|
636
|
-1,461
|
260
|
-3,614
|
ROE (net income / shareholders' equity)
|
4.47%
|
4.19%
|
3.94%
|
2.79%
|
5.11%
|
4.83%
|
ROA (Net income/ Total Assets)
|
1.31%
|
1.25%
|
1.48%
|
0.7%
|
0.99%
|
1.2%
|
Assets
1 |
1,64,257
|
1,68,122
|
1,38,078
|
2,12,173
|
2,83,921
|
2,26,680
|
Book Value Per Share
2 |
2,085
|
2,171
|
2,240
|
2,346
|
2,461
|
2,614
|
Cash Flow per Share
2 |
875.0
|
888.0
|
916.0
|
882.0
|
935.0
|
820.0
|
Capex
1 |
357
|
1,636
|
3,525
|
2,395
|
2,228
|
1,700
|
Capex / Sales
|
0.16%
|
0.7%
|
1.45%
|
1%
|
0.9%
|
0.65%
|
Announcement Date
|
28/06/18
|
28/06/19
|
26/06/20
|
30/06/21
|
30/06/22
|
29/06/23
|
|
1st Jan change
|
Capi.
|
---|
| +5.46% | 117M | | +19.79% | 72.09B | | -2.74% | 23.88B | | +10.76% | 8.89B | | +9.15% | 8.46B | | -17.39% | 8.29B | | +7.33% | 4.9B | | +17.69% | 4.34B | | -3.66% | 3.98B | | -2.54% | 3.89B |
Pharmaceuticals Wholesale
|